162 related articles for article (PubMed ID: 36402309)
1. Cefepime, not Piperacillin/Tazobactam use, for empirical treatment of bloodstream infections caused by Enterobacter spp.: Results from a population pharmacokinetic/pharmacodynamic analysis.
Shi Q; Huang C; Chen W; Wu S; Ji J; Ying C; Wu H; Xiao Y
Eur J Pharm Sci; 2023 Jan; 180():106334. PubMed ID: 36402309
[TBL] [Abstract][Full Text] [Related]
2. Empiric therapy for secondary peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation.
Eagye KJ; Kuti JL; Dowzicky M; Nicolau DP
Clin Ther; 2007 May; 29(5):889-899. PubMed ID: 17697907
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of antimicrobials for the empirical treatment of nosocomial pneumonia: a report from the OPTAMA Program.
Sun HK; Kuti JL; Nicolau DP
Crit Care Med; 2005 Oct; 33(10):2222-7. PubMed ID: 16215374
[TBL] [Abstract][Full Text] [Related]
4. A pharmacodynamic analysis of resistance trends in pathogens from patients with infection in intensive care units in the United States between 1993 and 2004.
Eagye KJ; Nicolau DP; Lockhart SR; Quinn JP; Doern GV; Gallagher G; Abramson MA
Ann Clin Microbiol Antimicrob; 2007 Oct; 6():11. PubMed ID: 17908321
[TBL] [Abstract][Full Text] [Related]
5. Comparison of five beta-lactam antibiotics against common nosocomial pathogens using the time above MIC at different creatinine clearances.
Kays MB
Pharmacotherapy; 1999 Dec; 19(12):1392-9. PubMed ID: 10600088
[TBL] [Abstract][Full Text] [Related]
6. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
[TBL] [Abstract][Full Text] [Related]
7. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
Xiao YH; Hu YJ
Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
[No Abstract] [Full Text] [Related]
8. Time Above All Else: Pharmacodynamic Analysis of β-Lactams in Critically Ill Patients.
Landmesser KB; Clark JA; Burgess DS
J Clin Pharmacol; 2022 Apr; 62(4):479-485. PubMed ID: 34614542
[TBL] [Abstract][Full Text] [Related]
9. Characterisation and clinical features of Enterobacter cloacae bloodstream infections occurring at a tertiary care university hospital in Switzerland: is cefepime adequate therapy?
Hilty M; Sendi P; Seiffert SN; Droz S; Perreten V; Hujer AM; Bonomo RA; Mühlemann K; Endimiani A
Int J Antimicrob Agents; 2013 Mar; 41(3):236-49. PubMed ID: 23313399
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic modeling of imipenem-cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program.
Ong CT; Kuti JL; Nicolau DP;
Surg Infect (Larchmt); 2005; 6(4):419-26. PubMed ID: 16433606
[TBL] [Abstract][Full Text] [Related]
11. Towards optimizing cefepime/tazobactam (WCK 4282) exposure to achieve efficacy against piperacillin/tazobactam-resistant ESBL infections: dose recommendations for various renal functions, including intermittent haemodialysis, in healthy individuals.
Muller AE; De Winter BCM; Koch BCP
J Antimicrob Chemother; 2024 May; 79(5):1093-1100. PubMed ID: 38507250
[TBL] [Abstract][Full Text] [Related]
12. Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Mimoz O; Elhelali N; Léotard S; Jacolot A; Laurent F; Samii K; Petitjean O; Nordmann P
J Antimicrob Chemother; 1999 Jul; 44(1):91-7. PubMed ID: 10459815
[TBL] [Abstract][Full Text] [Related]
13. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin).
Bauernfeind A; Schweighart S; Eberlein E; Jungwirth R
Infection; 1991; 19 Suppl 5():S264-75. PubMed ID: 1664418
[TBL] [Abstract][Full Text] [Related]
15. Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent.
Gill CM; Nicolau DP;
Clin Ther; 2023 Jan; 45(1):72-77. PubMed ID: 36593150
[TBL] [Abstract][Full Text] [Related]
16. Use of Monte Carlo simulation to optimize antibiotic selection for bloodstream infections caused by Enterobacteriaceae in Shandong Province, China.
Wang C; Bai Y; Li R; Shen C; Zhang J
Diagn Microbiol Infect Dis; 2020 Jun; 97(2):115039. PubMed ID: 32253072
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic/Pharmacodynamic Modeling of Seven Antimicrobials for Empiric Treatment of Adult Bloodstream Infections with Gram-Negative Bacteria in China.
Wang C; Hao W; Jin Y; Shen C; Wang B
Microb Drug Resist; 2020 Dec; 26(12):1559-1567. PubMed ID: 31794682
[No Abstract] [Full Text] [Related]
18. Piperacillin/tazobactam versus cefepime or carbapenems for cefoxitin-non-susceptible Enterobacter cloacae, Klebsiella aerogenes, Citrobacter freundii, Serratia marcescens and Morganella morganii bacteraemia in immunocompromised patients.
Lu B; Wong M; Ha D; Bounthavong M; Banaei N; Deresinski S; Diep C
J Antimicrob Chemother; 2023 Apr; 78(4):1009-1014. PubMed ID: 36879495
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States.
Koomanachai P; Bulik CC; Kuti JL; Nicolau DP
Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of continuous infusion of piperacillin/tazobactam in very elderly hospitalized patients and considerations for target attainment against Enterobacterales and Pseudomonas aeruginosa.
Cojutti PG; Morandin E; Baraldo M; Pea F
Int J Antimicrob Agents; 2021 Oct; 58(4):106408. PubMed ID: 34314808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]